Abstract
While drug-eluting stents have improved outcomes after percutaneous coronary intervention, 4-14% of patients in modern clinical trials still develop symptomatic restenosis. Future strategies for prevention of restenosis include modifications to the stent platform, the drug polymer or drug elution system, biocompatible stent coatings, use of bioresorbable scaffolds, and optimization of local and systemic anti-restenotic agents. Novel approaches to treating restenosis include a number of ongoing trials comparing treatment strategies with currently available drug eluting stents, use of drug coated balloons, and interventional strategies to increase stent expansion. While no single technology is likely to eliminate restenosis, the combination of these prevention and treatment strategies promises to improve the long-term outcomes of percutaneous coronary intervention.
| Original language | English (US) |
|---|---|
| Title of host publication | Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes |
| Publisher | Nova Science Publishers, Inc. |
| Pages | 263-283 |
| Number of pages | 21 |
| ISBN (Electronic) | 9781633213531 |
| ISBN (Print) | 9781633213463 |
| State | Published - Jan 1 2014 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Future strategies for preventing and treating coronary restenosis. / Armstrong, Ehrin J.; Messenger, John C.
Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes. Nova Science Publishers, Inc., 2014. p. 263-283.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Future strategies for preventing and treating coronary restenosis
AU - Armstrong, Ehrin J.
AU - Messenger, John C.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - While drug-eluting stents have improved outcomes after percutaneous coronary intervention, 4-14% of patients in modern clinical trials still develop symptomatic restenosis. Future strategies for prevention of restenosis include modifications to the stent platform, the drug polymer or drug elution system, biocompatible stent coatings, use of bioresorbable scaffolds, and optimization of local and systemic anti-restenotic agents. Novel approaches to treating restenosis include a number of ongoing trials comparing treatment strategies with currently available drug eluting stents, use of drug coated balloons, and interventional strategies to increase stent expansion. While no single technology is likely to eliminate restenosis, the combination of these prevention and treatment strategies promises to improve the long-term outcomes of percutaneous coronary intervention.
AB - While drug-eluting stents have improved outcomes after percutaneous coronary intervention, 4-14% of patients in modern clinical trials still develop symptomatic restenosis. Future strategies for prevention of restenosis include modifications to the stent platform, the drug polymer or drug elution system, biocompatible stent coatings, use of bioresorbable scaffolds, and optimization of local and systemic anti-restenotic agents. Novel approaches to treating restenosis include a number of ongoing trials comparing treatment strategies with currently available drug eluting stents, use of drug coated balloons, and interventional strategies to increase stent expansion. While no single technology is likely to eliminate restenosis, the combination of these prevention and treatment strategies promises to improve the long-term outcomes of percutaneous coronary intervention.
UR - http://www.scopus.com/inward/record.url?scp=84958669425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958669425&partnerID=8YFLogxK
M3 - Chapter
AN - SCOPUS:84958669425
SN - 9781633213463
SP - 263
EP - 283
BT - Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes
PB - Nova Science Publishers, Inc.
ER -